Frontlight ResearchEarly access
CompletedNo phase
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
Key facts
- Who runs it
- Abionic SA
- Where
- Chicago, Lexington, Providence, and Toledo, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- People taking part
- 544 people enrolled
- Started
- 10 Dec 2019
- Ended
- 28 Dec 2023
- Type of study
- Observational
- Treatments tested
- Blood sampling
- Record updated
- 30 January 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 1. Provision and understanding of signed and dated written informed consent by patient or legally designated representative prior to any mandatory study-specific procedures, sample collection, or analysis
- 2. Male or female, aged ≥ 18 years
- 3. Admitted to ICU on the day of screening, with expectation that patient will require ICU management for a minimum of 24 hours
Who cannot take part
- 1. Expected to die within 24 hours no matter what therapy is given, from the time of screening
- 5. Previous ICU admission during this hospital stay
- 2. Suffering on ICU admission or study entry from or known acute or chronic pancreatitis or pancreatic cancer)
- 3. Admitted to ICU due to elective cardiac surgery with an uncomplicated stay anticipated
- 6. Confirmed COVID-19 as reason for ICU admission
- 4. Patients having a valid Do Not Resuscitate order
Where in United States
- Northwestern UniversityChicago, United States
- Rush University Medical CenterChicago, United States
- University of KentuckyLexington, United States
- Rhode Island HospitalProvidence, United States
- Mercy Health St. VincentToledo, United States
About the trial
What the trial wants to find out
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at risk of sepsis as an aid in identifying sepsis.
The group in the trial
- Device: Blood sampling
Treatment: Blood sampling
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Prospective, Biomarker-result-blinded Observational Study Evaluating Immunoassay Measurements of Pancreatic Stone Protein Performed on Abionic's abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
- Publications
- Record updated
- 30 January 2024